

Index

- AABB practice guidelines for plasma transfusion 39
 abusive head trauma (AHT) 114
 acquired fibrinogen deficiency 40
 acute ischemic stroke
 carotid artery dissection as a cause of 94
 hypoglycemia and hyperglycemia 17
 acute normovolemic hemodilution (ANH) 36
 airway
 anatomical differences, neonates vs. adults 2
 management 4, 54, 114
 anemia, detection and treatment 34–5
 anesthetic-induced developmental neurotoxicity (AIDN) 159
 characterization of 160–3
 clinical studies 165–7
 mechanisms of 163–5
 summary points 167–8
 aneurysms 92–4
 animal studies, developmental
 neurotoxicity 159–60
 aberrant glial development 160–1
 abnormal neurogenesis 160
 altered dendritic development 160
 anesthetic effects spinal cord 161
 barbiturate exposure 163
 benzodiazepine exposure 163
 difficulties in extrapolating to humans 165
 effect of anesthetic durations and concentrations 161
 GABAergic agonists, effects of 162–3
 ketamine-induced neuroapoptosis 162
 mechanisms explaining 163–5
 neuroprotective agents 161–2
 neurocognitive function 161
 neuroinflammation 161
 nitrous oxide exposure 162
 pathological apoptosis 160
 propofol exposure 163
 volatile agents 163
 anticonvulsant effects of anesthetic agents 109
 anticonvulsants 96
 benzodiazepines 27–8
 interactions and adverse effects 109
 side effects of 102–3
 antifibrinolytics 37
 apoptosis
 agents increasing 162
 mechanisms of neuroapoptosis 163–5
 normal function of 161–2
 pathological 160
 arteriopathies, progressive 97–100
 arteriovenous malformations (AVMs) 95–6
 embolization case study 149–51
 asleep–awake–asleep approach, surgical resection of seizure foci 104–5
 astrocytomas 153
 atracurium 29
 AVMs (arteriovenous malformations) 95–6
 “awake” anesthesia for DBS placement (CCMC method) 67–8
 day of surgery 68–9
 DBS placement and testing 69–73
 implantable generator placement 73
 patient selection, preoperative evaluation and preparation 68
 awake craniotomy
 dexmedetomidine for 67
 surgical resection of seizure foci 104
 baclofen 65–6
 barbiturates 163
 sodium thiopental 26
 benzodiazepines 27–8, 163, 186
 blood conservation techniques
 intraoperative 35–41
 postoperative 41
 preoperative 34–5, 41
 blood donation 35
 blood loss, management of 6
 fetal surgery 81–2
 blood pressure autoregulation 9–10
 blood pressure control 93, 96, 150
 blood salvage 36
 blood sparing techniques 32
 hemostatic derangement during surgery 32–3
 neurosurgical bleeding 32
 patient blood management (PBM) 34
 transfusion morbidity and mortality 33–4
 blood volume calculation 39
 brain death, determination of 187–8
 brain injury
 anesthetic agents protecting against 17–18
 hyperthermia 16–17
 in perioperative setting 15–16
 see also traumatic brain injury (TBI)
 brain tumors *see* tumors
 brainstem
 brainstem auditory evoked responses (BAERs) 141
 gliomas 53
 monitoring 56
 bulbocavernosus reflex (BCR) 141–2
 Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) 66
 CAD (carotid artery dissection) 94–5
 cancer *see* radiotherapy
 carbon dioxide, partial pressure of arterial (PaCO₂) 12
 cardiac system 2
 cardiotoxicity, radiotherapy 154–5
 carotid artery dissection (CAD) 94
 cavernous malformations (CMs) 97
 CCVR (complex cranial vault reconstruction) 87
 cell death *see* apoptosis
 cell salvage during surgery 36
 central nervous system 1–2
 cerebellar astrocytomas 52
 cerebral blood flow (CBF)
 autoregulation curves 13
 control of in moyamoya patients 99
 effects of inhalational agents 24
 effects of intravenous agents 26–8
 cerebral metabolic requirement for oxygen (CMRO₂) 2
 cerebral perfusion pressure (CPP) 113–14
 calculation of 9
 effects of inhalational agents on 24
 cerebral salt wasting (CSW) 178–9

- cerebral venous sinus thrombosis (CVST) 94–5
 cerebrovascular disease 92
 aneurysms 92–4
 arteriovenous malformations (AVMs) 95–6
 carotid artery dissection (CAD) 94
 cavernous malformations (CMs) 97
 cerebral venous sinus thrombosis (CVST) 94–5
 moyamoya disease 97–100
 pediatric stroke 92
 vein of Galen malformation (VOGM) 96–7
 cerebrovascular physiology 9
 blood pressure autoregulation 9–10
 carbon dioxide, oxygen and glucose 12–13
 conclusions and illustrations 13
 intracranial hypertension and pressure autoregulation 10–12
 neurovascular coupling 12
 chemotherapy
 intra-arterial 151
 neurotoxicity 155
 Chiari malformations 53, 62
 child life specialists 68
 chloride measurements, variation in 174–5
 circulating blood volume 6, 39
 CMs (cavernous malformations) 97
 coagulopathy
 etiology 32–3
 massive transfusion protocol (MTP) 40–1
 monitoring of 36
 complex cranial vault reconstruction (CCVR) 87
 concussion 114
 congenital anomalies 58
 anesthetic management
 intraoperative management 60–1
 postoperative management 61
 preanesthetic evaluation 59–60
 cranial dysraphism 58–9
 spinal dysraphisms 59
 congenital neurosurgical lesions 58
 Chiari malformations 62
 congenital anomalies 58
 anesthetic management 59–61
 cranial dysraphism 58–9
 spinal dysraphisms 59
 hydrocephalus 62–3
 anesthetic management 63
 spina bifida occulta 61
 anesthetic considerations 61–2
 corpus callosotomy 106
 CPP *see* cerebral perfusion pressure
 cranial dysraphism 58–9
 anesthetic management of 59–61
 craniofacial surgery 86
 cranial vault reconstruction 87
 intraoperative management 88–90
 LeFort III osteotomy 87–8
 modified Pi procedure 87
 neuroendoscopic surgery 87
 postoperative concerns 90
 preoperative assessment and preparation 86–7
 spring-mediated cranioplasty 87
 cranioplasty, spring-mediated 87
 craniosynostosis
 elevated ICP 86–7
 repair of using ESC 126–9
 syndromic 86
 see also craniofacial surgery
 craniotomy
 aneurysm resection 93
 resection of seizure foci 104–5
 resection of tumor/mass lesion 143–5
 subdural grids and strips electrodes 106
 cryoprecipitate 40
 CSW (cerebral salt wasting) 178–9
 CVST (cerebral venous sinus thrombosis) 94–5
 cysts, treatment of 120–1
 death, definition of 187–8
 decompressive craniectomy 114–15
 deep brain stimulation (DBS) 65–7
 anesthetic considerations 67
 DBS placement in the operating room 69–73
 implantable pulse generator placement 73
 induction head frame placement and MRI scan 68–9
 patient selection, preoperative evaluation and preparation 68
 potential complications 73
 technological advances 73–4
 dendritic spine formation 160
 desflurane 25–6
 desmopressin (DDAVP), diabetes insipidus treatment 180
 dexmedetomidine 28, 164–5
 for “awake” craniotomies during DBS placement 67
 neuroprotective properties 20, 162
 for sedation in the ICU 186
 diabetes insipidus (DI) 179–80
 diagnostic cerebral angiography 147
 intraoperative management 148–9
 postoperative concerns 149
 preoperative issues 147–8
 diagnostic studies, anesthesia for 104
 distraction osteogenesis 87–8
 dorsal rhizotomy 142–3
 dysnatremia, postoperative 175
 dysraphisms
 cranial 58–9
 spinal 59
 dystonia 65
 DBS treatment 65–7
 EACA (epsilon aminocaproic acid) 37, 89
 electromyography (EMG) 140–1
 embolization 149–51
 as an adjuvant therapy for AVMs 95
 case studies 149
 EMG (electromyography) 140–1
 encephaloceles 58–9, 60
 endoscopic-assisted strip craniectomy (ESC) 126–7
 intraoperative management 129
 postoperative concerns 129
 preoperative assessment 127–9
 surgical procedure 127
 endoscopic third ventriculostomy (ETV) 121–2
 ependymomas 52–3, 153
 epilepsy surgery 102
 electrocorticography (ECoG) 105–6
 general anesthesia issues
 induction and maintenance 109–10
 monitoring 110
 neuromonitoring 110
 positioning of patient 108–9
 postoperative considerations 110
 takeaway concepts 111
 less invasive surgical techniques and implications 107–8
 nonfocal surgical resection 106–7
 perioperative considerations
 anesthesia for diagnostic studies 104
 epilepsy terminology 102
 imaging techniques 103–4
 preoperative evaluation 102–3
 subdural grids and strips electrodes 106
 surgical resection of seizure foci 104
 asleep–awake–asleep technique 104–5
 awake craniotomy 104
 vagal nerve stimulator (VNS) 108
 epsilon aminocaproic acid (EACA) 37, 89
 erythropoiesis stimulating agents (ESAs) 34–5
 ESC (endoscopic-assisted strip craniectomy) 126–9
 estradiol 163, 164
 etomidate 27

Index

- ETV (endoscopic third ventriculostomy) 121–2
 excitotoxicity, susceptibility of developing brain 15–16
- factor concentrates 40
 fentanyl 28
 fetal neurosurgery 77
 anesthetic management 80–3
 future directions 84–5
 hydrocephalus 77
 intrauterine fetal surgery 77
 myelomeningocele (MMC) 77–8
 postoperative concerns 83–4
 preoperative assessment and preparation 80
 fetal physiological development 79
 fibrinogen deficiency 40
 fluid management 6, 37
 in the ICU 184–5
 see also perioperative fluid therapy
 fresh frozen plasma (FFP) transfusion 39–40, 89
- GABAergic agonists 162–3
 GAS trial, general vs. awake-regional anesthesia 165–6, 167
 gastrointestinal toxicity 156
 general anesthesia
 asleep–awake–asleep approach 104–5
 for DBS surgery 67
 maintenance of 54
 neonatal and young childhood 166–7
 prenatal effects of 166
 general anesthesia issues, epilepsy surgery
 induction and maintenance 109–10
 monitoring 110
 neuromonitoring 110
 positioning of patient 108–9
 postoperative considerations 110
 takeaway concepts 111
 Glasgow Coma Scale 112
 glial cells, negative effect of anesthetic 160–1
 globus pallidus internus (GPi), deep brain stimulation 66
 dystonia treatment 66–7
 firing rates 67
 glucose levels 13, 110
 in acute ischemic stroke 17
 glycemic control 185
 in perioperative intravenous fluids 180
 greater occipital nerve 47
 greater occipital nerve block 49–50
 grids and strips electrodes, mapping of epileptic foci 106
- halogenated anesthetic agents 25–6
 head and neck anatomy 46
 occipital nerves 47
 trigeminal nerve 47
 head and neck blocks 45–6
 safety of 46
 hematological toxicity 155–6
 hemispherectomy 106–7
 hemodynamic stability 6
 hemodynamic support in the ICU 183–4
 hemostatic derangement during surgery 32–3
 hepatic system 2–3, 23
 Holliday and Segar formula for daily fluids 173
 homeostasis threat, intravenous normal saline 173–4
 hydrocephalus 62–3
 anesthetic management 63
 endoscopic third ventriculostomy (ETV) 121–2
 ETV treatment of occlusive 120
 in the postnatal period 77
 hyperglycemia 17, 180, 185
 hypertension, intracranial 10–12, 114–15, 116
 hyperventilation 12, 16, 116
 hypervolemic hemodilution (HH) 36
 hypocapnia 12, 16
 hypoglycemia 17, 180, 185
 hyponatremia 173, 177–8, 184
 cerebral salt wasting as one measure of 178–9
 following aneurysm resection 93–4
 nonosmotic secretion of ADH causing 184–5
 skeletal muscle as buffer against 177
 hypotension 73, 113
 hypothermia 36, 164
 neuroprotective benefit of 16, 116
 hypotonic fluids, avoidance of 177–8, 184–5
- ICP *see* intracranial pressure
 imaging techniques 103–4
 induced hypothermia 116
 induction of anesthesia 4, 54, 109
 infection
 cerebral venous sinus thrombosis (CVST) 94–5
 postoperative 73
 infraorbital nerve 47
 infraorbital nerve block 48–9
 inhaled anesthetic agents 23–5
 intensive care considerations 183
 agents for prophylaxis 187
 brain death 187–8
 concerns and risks 184–5
- fluid management 184
 hemodynamic support 183–4
 implications for the neurosurgical patient 184
 intracranial pressure monitoring 187
 key points 188
 respiratory support 183
 sedation 185
 dexmedetomidine 186
 opioids/benzodiazepines 185–6
 propofol 185
 seizures 186–7
 status epilepticus 187
 intra-arterial chemotherapy 151
 intraoperative neuromonitoring (IONM) 135
 brainstem auditory evoked responses (BAERs) 141
 bulbocavernosus reflex (BCR) 141–2
 electromyography (EMG) 140–1
 neurosurgical procedures utilizing 142–3
 craniotomy for resection of tumor/mass lesion 143–5
 dorsal rhizotomy 142–3
 tethered cord release 143
 somatosensory evoked potentials (SSEPs) 135–8
 transcranial motor evoked potentials (TcMEPs) 138–40
 intracranial cysts 120–1
 intracranial hemorrhage (ICH) 73
 intracranial hypertension 10–12, 114–15, 116
 intracranial pressure (ICP)
 autoregulation 10–12
 effects of inhalational agents 24
 effects of intravenous agents 26
 elevated in craniosynostosis patients 86–7
 inversely related to ABP 13
 medical management of raised 116
 monitoring of 115–16, 187
 reducing 16
 refractory intracranial hypertension 114–15
 intrathecal baclofen (ITB) therapy 65–6
 intrauterine fetal surgery 77
 intravenous anesthetic agents 19–20, 26–8
 intravenous fluids *see* perioperative fluid therapy
 intravenous normal saline and the threat to homeostasis 173–4
 ion-specific electrode (ISE) technology 174
 IONM *see* intraoperative neuromonitoring

- isoflurane 25
 neuroprotective properties of 18
- ketamine 19, 27
 neurotoxic effects of 19, 162
 for radiotherapy 157
- L-carnitine 164
- laser Doppler flowmetry (LDF) 13
- laser interstitial thermal therapy (LITT) 107, 129–30
 complications and postoperative concerns 132
 intraoperative management 131–2
 preoperative issues 130–1
 surgical procedure 130
- LeFort III osteotomy with distraction osteogenesis 87–8
- lesser occipital nerve 47
- levetiracetam 187
- lidocaine 19
- lithium 164
- LITT *see* laser interstitial thermal therapy (LITT)
- liver function 2–3
- local anesthetics, neuroapoptosis 165
- maintenance of anesthesia 5–6, 54, 109
- mandibular nerve 47
- mandibular nerve block 49
- mass lesions 115
- massive transfusion protocol (MTP) 40–1
- maximal allowable blood loss (MABL) 6, 39
- mechanical ventilation 183
- medulloblastomas 52, 153
- melatonin 164
- MEPs (motor evoked potentials) 138–40
- midazolam 27–8
- minimally invasive neurosurgery 120
 endoscopic-assisted strip craniectomy (ESC) for cranosynostosis repair 126–7
 ESC surgical procedure 127
 intraoperative management 129
 postoperative concerns 129
 preoperative assessment 127–9
- MRI-guided laser interstitial thermal therapy (LITT) 129–30
 complications and postoperative concerns 132
 intraoperative management 131–2
 preoperative issues 130–1
 surgical procedure 130
- ventricular neuroendoscopy 120–1
 avoidance of complications and postoperative concerns 126
- endoscopic third ventriculostomy (ETC) 121–2
 intraoperative management 124–6
 preoperative issues 122–4
- modeling effect of too much water versus too much salt 175–7
- modified Pi procedure 87
- MOMS (Management of Myelomeningocele) trial 78, 84
- morphine 161
- motor evoked potentials (MEPs) 138–40
 effects of inhalational agents on 24
- moyamoya disease/syndrome 97–100
 diagnostic cerebral angiography, case study 147–9
- MRI-guided laser interstitial thermal therapy (LITT) 129–32
- muscle relaxants 28–9
- myelodysplasia
 Arnold-Chiari malformation (type II) in 53
 risk for latex sensitivity 59
- myelomeningocele (MMC) 77–8
 fetal surgery to repair anesthetic management 80–3
 future of 84–5
 see also spina bifida occulta
- myelosuppression 155–6
- narcotics 165
- neural tube defects *see* myelomeningocele (MMC)
- neuroembolization 149
 case studies 149
 intraoperative management 150–1
 postoperative concerns 151
 preoperative issues 149–50
- neuroapoptosis, anesthesia-induced factors characterizing 160–3
 mechanisms explaining 163–5
- neurocognitive function
 animal studies 161
 link between surgery and poor outcomes 166–7
 no link between IQ and anesthesia exposure 167
- neuroendoscopic surgery 87
 endoscopic third ventriculostomy 121–2
- neurogenesis, abnormal 160
- neuroimaging techniques 103–4
- neuroinflammation 161
- neurointerventional radiology 147
 diagnostic cerebral angiography 147–9
 intra-arterial chemotherapy 151
 neuroembolization 149–51
- neuromonitoring *see* intraoperative neuromonitoring (IONM)
- neuropharmacology 23
 halogenated anesthetic agents 25–6
 inhaled anesthetic agents 23–5
 intravenous anesthetic agents 26–8
 muscle relaxants 28–9
 opioids 28
- neuroprotective strategies 15
 brain injury in the perioperative setting 15–16
 pharmacologic interventions
 anesthetic neuroprotection 17–18
 intravenous anesthetic agents 19–20
 volatile anesthetic agents 18–19
 physiologic interventions 16–17
 summary 20
- neurosurgical bleeding 32
- neurosurgical patient 1
 developmental aspects 1–3
 intraoperative management 4–6
 postoperative disposition 6–7
- nitrous oxide 23–5
 neuroprotective effect 18
 neurotoxic effects of 162
- NMDA receptor antagonists
 cell death induced by 164
 see also ketamine; nitrous oxide
- nonfocal surgical resection 106–7
- normal saline (NS) 109
 homeostasis threat 173–4
- occipital encephaloceles 59
- occipital nerves 47
 greater occipital nerve block 49–50
 scalp block 68–9
- occult spinal dysraphism (OSD) 61–2
- ophthalmic nerve 47
- ophthalmic nerve block 47–8
- opioids 28, 186
 apoptosis effect 161
- osmotic diuretics 16
- osteotomies, cranial 87–8
- oxygen, partial pressures of arterial O₂ (PaO₂) 12–13
- pain perception by fetus 83
- Parkinson's disease (PD), deep brain stimulation (DBS) 65
- partial pressure of arterial CO₂ (PaCO₂) 12
- patient blood management (PBM) 34, 41
- PEEP (positive end expiratory pressure) 183
- pentobarbital 163
- perioperative fluid therapy 173
 glucose or no glucose 180
 intravenous normal saline and the threat to homeostasis 173–4

Index

- perioperative fluid therapy (cont.)
 modeling effect of too much water
 vs. too much salt 175–7
 postoperative dysnatremia 175
 postoperative renal Na⁺ and water
 handling 177
 cerebral salt wasting (CSW) 178–9
 diabetes insipidus (DI) 179–80
 syndrome of inappropriate ADH
 secretion (SIADH) 177–8
 variations in sodium and chloride
 measurements 174–5
 phenobarbital 163
 phenytoin 109, 130, 187
 plasma transfusion 39–40
 platelets, transfusion of 39
 positioning of patient 4–5, 55
 epilepsy surgery 108–9
 for ESC procedures 127, 129
 neonate 60
 prone position 55
 sitting position 55–6
 posterior fossa craniotomy 52, 57
 intraoperative management
 airway management 54
 induction and maintenance of
 anesthesia 54
 monitoring 56
 positioning 55–6
 neurosurgical lesions
 Chiari malformations 53
 tumors 52–3
 perioperative concerns 53–4
 postoperative management 56–7
 postoperative disposition of patient
 6–7
 postoperative dysnatremia 175
 pregnancy, maternal physiologic
 changes during 78–9
 preoperative assessment and planning 3
 propofol 26–7
 neuroprotective effect of 19
 neurotoxicity of 163
 for sedation during radiotherapy 157
 prothrombin complex concentrates
 (PCCs) 40
 pulmonary toxicity from radiotherapy
 155
 radiotherapy 153
 airway problems 154
 anesthesia management 156
 challenges 156–7
 recovery 157
 CNS tumors 153–4
 goals of 154
 secondary cancer risk 156
 toxicity from treatment 154–6
 rating scales, dystonia 66–7
 red blood cells, transfusion of 6, 38–9
 reference change value (RCV) 174–5
 reference interval (RI) 174
 refractory intracranial hypertension
 114–15
 treatment of 116
 regional anesthesia 45–6
 clinical anatomy of the head and
 neck 46
 occipital nerves 47
 trigeminal nerve 47
 illustrative figures 50
 safety of head and neck blocks 46
 trigeminal nerve blocks
 greater occipital nerve 49–50
 infraorbital nerve (V2) 48–9
 mandibular nerve (V3) 49
 ophthalmic nerve (V1) 47–8
 remifentanyl 28
 renal system 2
 postoperative renal problems
 177–80
 respiratory support in the ICU 183
 retinoblastoma treatment 151
 rocuronium 28–9
 salt and water *see* perioperative fluid
 therapy
 secondary dystonia, DBS treatment 65
 opioid narcotics 71
 SEEG (stereo-electroencephalography)
 107–8
 seizures
 control of in the ICU 186–7
 status epilepticus 187
 surgical resection of foci 104–5
 sevoflurane 25
 neuroprotective effect 18
 SIADH (syndrome of inappropriate
 ADH secretion) 177–8
 skull fractures 115
 sodium (Na⁺)
 measurement variations 174–5
 modeling volume and concentration
 175–7
 postoperative dysnatremia 175
 postoperative renal problems
 177–80
 sodium thiopental 26
 somatosensory evoked potentials
 (SSEPs) 135–8
 effects of inhalational agents
 on 24
 spasticity
 intrathecal baclofen treatment 65–6
 selective dorsal rhizotomies 142–3
 spina bifida occulta 61
 anesthetic considerations 61–2
 spinal cord, effects of anesthesia 161
 spinal dysraphisms 59
 anesthetic management of 59–61
 spring-mediated cranioplasty 87
 SSEPs (somatosensory evoked
 potentials) 135–8
 status epilepticus 187
 stereo-electroencephalography (SEEG)
 107–8
 stereotactic skull frame placement
 131–2
 stroke 92
 carotid artery dissection as cause of
 94
 succinylcholine 28
 contraindications to the use of 4
 suprazygomatic maxillary nerve block
 48–9
 surgical resection of seizure foci 104
 asleep–awake–asleep technique
 104–5
 awake craniotomy 104
 syndrome of inappropriate ADH
 secretion (SIADH) 177–8
 TcMEPs (transcranial motor evoked
 potentials) 138–40
 technological advances
 3D-imaging, radiation therapy 154
 DBS surgery 73–4
 in minimally invasive surgery 63
 stereotactic techniques 129–30
 tethered spinal cord syndrome (TCS) 62
 spina bifida occulta 61
 thiopental 19, 116
 thromboelastography (TEG) 36
 thromboelastometry (ROTEM) 36
 toxicity from radiotherapy 154
 cardiotoxicity 154–5
 chemotherapy toxicity 155
 gastrointestinal toxicity 156
 hematological toxicity 155–6
 neuroendocrine dysfunction 156
 pulmonary toxicity 155
 secondary cancer risk 156
 tranexamic acid (TXA) 37, 89
 transcranial motor evoked potentials
 (TcMEPs) 138–40
 transfusion
 of fresh frozen plasma 39–40
 massive transfusion protocol (MTP)
 40–1
 of platelets 39
 of red blood cells 6, 38–9
 risks of, mitigating 89–90
 scope and associated morbidity and
 mortality 33–4
 traumatic brain injury (TBI) 112–13
 approaches to
 abusive head trauma 114
 airway management 114
 cerebral perfusion pressure
 113–14

concussion 114	predictors of poor outcome	vein of Galen malformation (VOGM)
systemic hypotension 113	following 116–17	96–7
cerebral resuscitation	trigeminal nerve 47	neonate case study 149
induced hypothermia	trigeminal nerve blocks	venous air embolism (VAE) 56,
116	greater occipital nerve 49–50	73, 110
intracranial pressure monitoring	infraorbital nerve (V2) 48–9	ventilatory support 183
115–16	mandibular nerve (V3) 49	ventricular neuroendoscopy
medical management of raised	ophthalmic nerve (V1) 47–8	120–1
ICP 116	tumors 52–3, 153–4	complications and postoperative
Glasgow Coma Scale and	biopsy 121	concerns 126
modification for young	involving the airway 154	endoscopic third ventriculostomy
children 112	resection in posterior fossa 143–5	(ETV) 121–2
guidelines for acute medical	ultrasound-guided occipital nerve	intraoperative management
management of severe	block 50	124–6
TBI 117		preoperative issues 122–4
indications for surgery	vagal nerve stimulator (VNS), epilepsy	volatile anesthetic agents 18–19, 80–1,
mass lesions 115	treatment 108	163
refractory intracranial	vascular access 4–5	
hypertension 114–15	vasopressin deficiency 179	water and salt <i>see</i> perioperative fluid
skull fractures 115	vasopressin infusion for diabetes	therapy
surgical decision making and	insipidus 179–80	
perioperative communication	vecuronium 28–9	xenon 18–19, 164
115		